8 sources checked · Left, Center, and Right included · 56m ago
Different Spin
FDA adds rare vision-loss warning to popular GLP-1 drugs
CNBC and Al.com (Alabama News) describe the same event in different terms.
2 Left5 Center1 Right
Same story. Different framing.Left, center, and right outlets are covering the same event. Here’s how each side worded it.
DIFFERENT SPIN
HOW EACH SIDE WORDED IT
Left-leaningCenter-leftFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBCMostly Factual
vs
Right-leaningCenter-rightOzempic, Wegovy and Zepbound get new FDA warning over rare conditionAl.com (Alabama News)Mostly Factual
Center baseline · WJW FOX8 (Nexstar, Cleveland)HighFDA adds rare vision-loss warning to popular GLP-1 drugs
As of November 10, 2026 at 2:50 PM, this is how Optics News reads the wording differences in this story.
What happenedPopular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday.
The headline splitThe left frames it as "FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound". The right frames it as "Ozempic, Wegovy and Zepbound get new FDA warning over rare condition".
Match confidenceHigh confidence. 8 sources checked, Left/Center/Right all represented. Best read as a clear framing signal — not a fact-check.
Same-event confidenceHigh
8 sources across Left, Center, and Right all describe the same event.
Framing confidenceModerate
74/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
CNBC · Center-left · News report
CenterFDA adds rare vision-loss warning to popular GLP-1 drugs
WJW FOX8 (Nexstar, Cleveland) · Center · News report
Right / center-rightOzempic, Wegovy and Zepbound get new FDA warning over rare condition
FDA adds rare vision-loss warning to popular GLP-1 drugs
Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators an...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
